AstraZeneca PLC (AZN)
Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-06 |
| Earnings Call | 2025-11-06 |
| Avg EPS Estimate | 1.1347 |
| Low EPS Estimate | 1.13 |
| High EPS Estimate | 1.14 |
| Revenue | |
| Avg Revenue Forecast | 14,768,595,280 |
| Low Revenue Forecast | 14,548,000,000 |
| High Revenue Forecast | 14,900,000,000 |
AZN Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $7,107,999,744 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.664 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 0.863 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $32,938,999,808 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
AZN Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $19,128,000,512 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $13,388,999,680 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $8,967,874,560 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 82.26% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 24.12% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 14.68% | Net profit margin, which reflects overall profitability. |
AZN Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 73.51% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $32,938,999,808 | Used together with cash and EBITDA to assess debt-paying ability. |
AZN Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 11.70% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 27.60% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for AZN (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $81.15 | Latest stock trading price |
| Price Target (High) | $101 | Analyst highest expected price |
| Price Target (Low) | $81 | Analyst lowest expected price |
| Price Target (Average) | $93.25 | Average target price across analysts |
| Price Target (Median) | $94.98 | Median of target prices |
| Average Rating Score | 1.36 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | strong_buy | Consensus rating |
| Analyst Coverage Count | 11 | Number of analysts providing estimates |
| Cash Holdings | $7,107,999,744 | Total cash held by the company |
| Cash per Share | $4.59 | Cash value per outstanding share |
| Total Debt | $32,938,999,808 | Company's total debt |
| Quick Ratio | 0.664 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 0.863 | Overall short-term liquidity |
| Debt/Equity Ratio | 73.51% | Leverage ratio: Debt / Equity |
| EBITDA | $19,128,000,512 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $56,500,998,144 | Total company revenue |
| Revenue per Share | $3.0246 | Total revenue divided by shares outstanding |
| Gross Profit | 82.26% | Revenue minus cost of goods sold |
| Return on Assets | 8.28% | Net income / Total assets |
| Return on Equity | 19.67% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 27.60% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 11.70% | Year-over-year revenue growth |
| Gross Margin | 82.26% | Gross profit / Total revenue |
| EBITDA Margin | 33.85% | EBITDA / Revenue |
| Operating Margin | 24.12% | Operating income / Revenue |
| Profit Margin | 14.68% | Net income / Revenue |
| Free Cash Flow | $8,967,874,560 | Cash left after capital expenditures |
| Operating Cash Flow | $13,388,999,680 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |